{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:18:50Z","timestamp":1773465530448,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000266","name":"EPSRC","doi-asserted-by":"publisher","award":["EP\/R024804\/1"],"award-info":[{"award-number":["EP\/R024804\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"EPSRC","doi-asserted-by":"publisher","award":["EP\/S012265\/1"],"award-info":[{"award-number":["EP\/S012265\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI134091"],"award-info":[{"award-number":["R01AI134091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R24AI118397"],"award-info":[{"award-number":["R24AI118397"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["761104"],"award-info":[{"award-number":["761104"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Unitaid"},{"name":"Wellcome Trust and Medical Research Council for the AGILE phase","award":["BB\/N022505\/1"],"award-info":[{"award-number":["BB\/N022505\/1"]}]},{"name":"Wellcome Trust and Medical Research Council for the AGILE phase","award":["BB\/R00904X\/1"],"award-info":[{"award-number":["BB\/R00904X\/1"]}]},{"name":"Wellcome Trust and Medical Research Council for the AGILE phase","award":["BB\/R018863\/1"],"award-info":[{"award-number":["BB\/R018863\/1"]}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"British Council\/BEIS","award":["332228521"],"award-info":[{"award-number":["332228521"]}]},{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","award":["MR\/R010145\/1"],"award-info":[{"award-number":["MR\/R010145\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US Food and Drug Administration","award":["75F40120C00085"],"award-info":[{"award-number":["75F40120C00085"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This article provides a brief overview of drug resistance to antiviral therapy as well as known and emergent variability in key SARS-CoV-2 viral sequences. The purpose is to stimulate deliberation about the need to consider drug resistance prior to widespread roll-out of antivirals for SARS-CoV-2. Many existing candidate agents have mechanisms of action involving drug targets likely to be critical for future drug development. Resistance emerged quickly with monotherapies deployed for other pulmonary viruses such as influenza virus, and in HIV mutations in key drug targets compromised efficacy of multiple drugs within a class. The potential for drug resistance in SARS-CoV-2 has not yet been rigorously debated or assessed, and we call for more academic and industry research on this potentially important future threat prior to widespread roll-out of monotherapies for COVID-19 treatment and prevention.<\/jats:p>","DOI":"10.1093\/jac\/dkab189","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:13:55Z","timestamp":1620933235000},"page":"2230-2233","source":"Crossref","is-referenced-by-count":23,"title":["Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6582-0275","authenticated-orcid":false,"given":"Julian A.","family":"Hiscox","sequence":"first","affiliation":[{"name":"Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK"},{"name":"Infectious Diseases Horizontal Technology Centre (ID HTC), A*STAR, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-0967","authenticated-orcid":false,"given":"Saye H.","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-2037","authenticated-orcid":false,"given":"James P.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-7651","authenticated-orcid":false,"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK"},{"name":"Centre of Excellence in Long acting Therapeutics (CELT), University of Liverpool, Liverpool, L69 3BX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"2021081309085036900_dkab189-B1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/rccm.202008-3265OC","article-title":"Tissue-specific Immunopathology in Fatal COVID-19","volume":"203","author":"Dorward","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2021081309085036900_dkab189-B2","first-page":"133","article-title":"Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report","volume":"58","author":"Group","year":"2020","journal-title":"N Engl J Med"},{"key":"2021081309085036900_dkab189-B3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/med.21724","article-title":"The recent outbreaks of human coronaviruses: a medicinal chemistry perspective","volume":"41","author":"Pillaiyar","year":"2021","journal-title":"Med Res Rev"},{"key":"2021081309085036900_dkab189-B4","doi-asserted-by":"crossref","first-page":"e3001000","DOI":"10.1371\/journal.pbio.3001000","article-title":"Monitor for COVID-19 vaccine resistance evolution during clinical trials","volume":"18","author":"Kennedy","year":"2020","journal-title":"PLoS Biol"},{"key":"2021081309085036900_dkab189-B5","doi-asserted-by":"crossref","first-page":"100733","DOI":"10.1016\/j.drup.2020.100733","article-title":"COVID-19 update: the race to therapeutic development","volume":"53","author":"Twomey","year":"2020","journal-title":"Drug Resist Updat"},{"key":"2021081309085036900_dkab189-B6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.11604\/pamj.supp.2020.35.2.23713","article-title":"Treatment of COVID-19: implications for antimicrobial resistance inAfrica","volume":"35","author":"Iwu","year":"2020","journal-title":"Pan Afr Med J"},{"key":"2021081309085036900_dkab189-B7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/20469047.2020.1853350","article-title":"Global emerging resistance in pediatric infections with TB, HIV, and Gram-negative pathogens","volume":"41","author":"Enane","year":"2020","journal-title":"Paediatr Int Child Health"},{"key":"2021081309085036900_dkab189-B8","doi-asserted-by":"crossref","first-page":"100721","DOI":"10.1016\/j.drup.2020.100721","article-title":"Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses","volume":"53","author":"Artese","year":"2020","journal-title":"Drug Resist Updat"},{"key":"2021081309085036900_dkab189-B9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect Drug Resist"},{"key":"2021081309085036900_dkab189-B10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J Infect Dis"},{"key":"2021081309085036900_dkab189-B11","doi-asserted-by":"crossref","first-page":"104780","DOI":"10.1016\/j.antiviral.2020.104780","article-title":"Put a cork in it: plugging the M2 viral ion channel to sink influenza","volume":"178","author":"Jalily","year":"2020","journal-title":"Antiviral Res"},{"key":"2021081309085036900_dkab189-B12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","article-title":"Influenza and antiviral resistance: an overview","volume":"39","author":"Lampejo","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021081309085036900_dkab189-B13","first-page":"Doc04","article-title":"Influenza viruses - antiviral therapy and resistance","volume":"5","author":"Duwe","year":"2017","journal-title":"GMS Infect Dis"},{"key":"2021081309085036900_dkab189-B14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","article-title":"Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: an Open-label Randomized, Controlled, Phase IIb\/III Trial","volume":"151","author":"Hung","year":"2017","journal-title":"Chest"},{"key":"2021081309085036900_dkab189-B15","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2021081309085036900_dkab189-B16","doi-asserted-by":"crossref","first-page":"veaa061","DOI":"10.1093\/ve\/veaa061","article-title":"Temporal signal and the phylodynamic threshold of SARS-CoV-2","volume":"6","author":"Duchene","year":"2020","journal-title":"Virus Evol"},{"key":"2021081309085036900_dkab189-B17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature14594","article-title":"Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa","volume":"524","author":"Carroll","year":"2015","journal-title":"Nature"},{"key":"2021081309085036900_dkab189-B18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","article-title":"SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology","volume":"101","author":"Ogando","year":"2020","journal-title":"J Gen Virol"},{"key":"2021081309085036900_dkab189-B19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13073-020-00763-0","article-title":"Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein","volume":"12","author":"Davidson","year":"2020","journal-title":"Genome Med"},{"key":"2021081309085036900_dkab189-B20","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"2021081309085036900_dkab189-B21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"key":"2021081309085036900_dkab189-B22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(20)30912-9","article-title":"SARS-CoV-2 and the human-animal interface: outbreaks on mink farms","volume":"21","author":"Koopmans","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2021081309085036900_dkab189-B23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.abe5901","article-title":"Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans","volume":"371","author":"Oude Munnink","year":"2020","journal-title":"Science"},{"key":"2021081309085036900_dkab189-B24","doi-asserted-by":"crossref","first-page":"m4944","DOI":"10.1136\/bmj.m4944","article-title":"Covid-19: what have we learnt about the new variant in the UK?","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"2021081309085036900_dkab189-B25","article-title":"Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa","author":"Tegally","year":"2020","journal-title":"MedRxiv"},{"key":"2021081309085036900_dkab189-B26","first-page":"00367","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"S0092-8674","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"2021081309085036900_dkab189-B27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"2021081309085036900_dkab189-B28","doi-asserted-by":"crossref","first-page":"e00221-18","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"2021081309085036900_dkab189-B29","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"2021081309085036900_dkab189-B30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"2021081309085036900_dkab189-B31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1097\/QAD.0b013e328273bbf5","article-title":"Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: a 6 year follow-up analysis of a large observational database","volume":"21","author":"Mauro","year":"2007","journal-title":"AIDS"},{"key":"2021081309085036900_dkab189-B32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/135965350601100503","article-title":"Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome","volume":"11","author":"Tozzi","year":"2006","journal-title":"Antivir Ther"},{"key":"2021081309085036900_dkab189-B33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.aids.0000174455.01369.ad","article-title":"Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients","volume":"19","author":"Zaccarelli","year":"2005","journal-title":"AIDS"},{"key":"2021081309085036900_dkab189-B34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","article-title":"Synergistic and antagonistic drug combinations against SARS-CoV-2","volume":"29","author":"Bobrowski","year":"2020","journal-title":"Mol Ther"},{"key":"2021081309085036900_dkab189-B35","article-title":"Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells","author":"Nguyenla","year":"2020","journal-title":"BioRxiv"},{"key":"2021081309085036900_dkab189-B36","article-title":"Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2","author":"Jeffreys","year":"2020","journal-title":"BioRxiv"},{"key":"2021081309085036900_dkab189-B37","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/v12101164","article-title":"Amplicon-based detection and sequencing of SARS-CoV-2 in nasopharyngeal swabs from patients with COVID-19 and identification of deletions in the viral genome that encode proteins involved in interferon antagonism","volume":"12","author":"Moore","year":"2020","journal-title":"Viruses"},{"key":"2021081309085036900_dkab189-B38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(20)31757-8","article-title":"Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study","volume":"396","author":"Young","year":"2020","journal-title":"Lancet"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2230\/39711670\/dkab189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2230\/39711670\/dkab189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T08:18:58Z","timestamp":1672129138000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/9\/2230\/6303573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,18]]},"published-print":{"date-parts":[[2021,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab189","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,18]]}}}